| Name | Title | Contact Details |
|---|
The University of Maryland Medical System (UMMS) is a university-based regional health care system focused on serving the health care needs of Maryland. We bring innovation, discovery and research to the care we provide all while educating the state`s future physicians and health care professionals through our partnership with the University of Maryland School of Medicine and the UM Schools of Nursing, Pharmacy, Social Work and Dentistry in Baltimore. As one of the largest private employers in the state, the health system`s 25,000 employees and 4,000 affiliated physicians provide primary and specialty care in more than 150 locations and at 13 hospitals. UMMS` flagship academic campus, the University of Maryland Medical Center in Baltimore, is recognized regionally and nationally for excellence and innovation in specialized care. Our acute care and specialty rehabilitation hospitals serve urban, suburban and rural communities and are located in 13 counties across the state. In addition, UMMS operates health insurance plans serving Medicare and Medicaid members.
The Warner Babcock Institute for Green Chemistry is dedicated to the development of non toxic, environmentally benign and sustainable technological solutions for society. Focused on the practical application of Green Chemistry, we assist our industry partners in the development of sustainable technologies, products, and processes at the molecular level. Our emphasis is on the practical application of Green Chemistry concepts to drive cost savings and minimize time to market. The Warner Babcock Institute for Green Chemistry was founded in 2007 by Dr. John C. Warner, one of the founders of the field and co-author of seminal book Green Chemistry: Theory and Practice, which first defined the Twelve Principles of Green Chemistry.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.
Greene County Health Care (GCHC) Inc. is a non-profit organization that provides high quality, integrated, and affordable health care to residents of Greene, Pitt, and Pamlico counties in eastern North Carolina, with a focus on the uninsured, underinsu...
Lake Shore Inn Nursing Home is a Waseca, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.